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license (http://creativecommons.org/Abstract Purpose: The aim of the current study is to disseminate long-term “real-world”
data on mortality and device therapies in primary and secondary prevention implantable car-
dioverter defibrillator (ICD) recipients on the island of Crete.
Methods: We analyzed data for all consecutive patients who received an ICD in our tertiary
university hospital from 1993 until December 2013. Follow-up visits were performed every 6
months or more frequently when indicated. Survival status was recorded, and all stored epi-
sodes during interrogation were registered and classified as appropriate or inappropriate.
Results: In total, 854 patients received an ICD; 623 (73%) for primary and 231 (27%) for second-
ary prevention. Most of these patients (490) suffered from ischemic cardiomyopathy. During
the mean follow-up of 12.4  7.8 years, 218 (25.5%) patients died; 19.7% in the primary pre-
vention group (pZ0.008) and 41.1% in the secondary prevention group. Overall, 248 patients
(29%) received appropriate therapy; however, the percentage was significantly higher in the
secondary prevention group (44.2%) than in primary prevention group (23.4%). The cumulative
incidence of inappropriate therapies during the mean follow-up period was 11.6%. Lead-
related complications were noted in 49 patients (5.7%), while only 13 patients (1.5%) suffered
device-related infections..gr (E.M. Kanoupakis).
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248 E.M. Kanoupakis et al.Conclusions: The long-term data related to clinical outcomes in ICD recipients in our center
are in accordance with those of other international centers and confirm the high efficacy
and safety of these devices in preventing sudden cardiac death.
ª 2016 Hellenic Cardiological Society. Publishing services by Elsevier B.V. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Thirty-five years after its first implantation in humans, the
implantable cardioverter defibrillator (ICD) remains the
cornerstone therapy for the prevention of sudden cardiac
death (SCD).1 This therapy’s clinical superiority over opti-
mum pharmacological therapy has been validated in a
number of well-designed prospective randomized trials.2e4
These clinical trials were performed in well-selected and
protected patient populations, and the implications for
routine clinical practice have always been an attractive
challenge.
The benefits of ICDs in reducing all-cause mortality have
been proven in both patients surviving a life-threatening
event (secondary prevention),2,3,5 and those at high risk,
but without such an event (primary prevention).4,6e8
Beyond the borders of randomized clinical trials, a
relative scarcity of data exists on the long-term follow-up
outcomes of such patients in the context of tertiary
hospital-ICD implantation centers.
Therefore, the aim of the current study is to disseminate
long-term “real-world” data on mortality and device ther-
apies in primary and secondary prevention in ICD recipients
on the island of Crete.
2. Methods
2.1. Patient population
From 1993, when the first ICD was implanted in a patient on
the island of Crete, until today, the Electrophysiology Lab
(EP) of the Cardiology Department at Heraklion University
Hospital remains the only implantation center on the is-
land. Therefore, all patients on our island, who were sub-
jected to ICD implantation from 1993 to December 31,
2013, were included.
Device implantations were based on international
guidelines, and all implantations were performed after
approval by the Central Board of Health (KESY), as required
by law.
The study population was grouped according to pre-
vention type: primary or secondary for SCD, and the
implanted device type: single-chamber ICD, dual-chamber
ICD, or Cardiac Resynchronization Therapy - Defibrillator
(CRT-D).
All patients were followed from the time of their initial
ICD implantation until their death from any cause or until
the end of the study period.
All-cause mortality and appropriate defibrillator thera-
pies (ATP and shocks) were considered the primary end-
points of the study, while device replacements, device-related complications and inappropriate shocks were
considered as secondary endpoints.
The study was conducted in accordance with the Decla-
ration of Helsinki (1989),World Medical Association (WMA),
as revised in Edinburgh (2000). No ethical approval is
required for retrospective registry-based studies in Greece.
2.2. Devices
Implanted systems, devices and electrodes, were manu-
factured by Biotronik (Berlin, Germany), Boston Scientific
(Natick, MA, USA, formerly CPI, Guidant (St. Paul, MN,
USA)), ELA Medical Inc. (Sorin Group), Medtronic (Minne-
apolis, MN, USA) and St. Jude Medical (St. Paul, MN, USA).
2.3. Follow-up and device interrogation
Baseline clinical characteristics for all patients were
collected preoperatively and were recorded by the im-
planters, including demographics, medical history, and un-
derlying cardiac disease. After the implantation procedure,
all of the possible perioperative complications and initial ICD
programming characteristics were recorded. Periodical
follow-up visits were performed every 6 months or more
frequently when indicated. At each visit, device interroga-
tion was performed by electrophysiologists. During interro-
gation, all stored episodes were registered and classified as
appropriate or inappropriate. All other device-related
complications and clinical observations were also recor-
ded. Survival status was retrieved by the patient’s relatives
(after communication, in case of loss of a date), and in most
cases was confirmed after contact with their physicians.
2.4. Statistical analysis
Summary descriptive statistics are presented as frequency
(%), or mean þ/ standard deviation, as appropriate.
Comparisons between primary and secondary prevention
groups were performed using independent samples t-test
and chi-square test for continuous and categorical vari-
ables, respectively. Kaplan-Meier product-limit estimate
survival curves were constructed and compared via the log-
rank test. All statistical tests were two-sided with a 5% level
of significance using the IBM-SPSS software package.
3. Results
3.1. Demographics
During the period 1993-2013, a total of 854 patients were
subjected to initial ICD implantation. The annual
Table 1 Patient baseline clinical characteristics.
Primary
prevention
nZ623
Secondary
prevention
nZ231
p
Age (years) 62.511.3 63.912.6 0.129
Sex 0.021
Male 562 (90.21%) 195 (84.42%)
Female 61 (9.79%) 36 (15.58%)
Ejection
Fraction (%)
2813 399 0.01
Underlying
heart disease
<0.001
ICM 358 (57.46%) 132 (57.14%)
DCM 199 (31.94%) 66 (28.57%)
HCM 35 (5.62%) 6 (2.60%)
Channelopathy 31 (4.98%) 27 (11.69%)
History 0.03
MI 307 (49.28%) 118 (51.08%)
GABG 184 (29.53%) 39 (16.88%)
PCI 169 (27.13%) 75 (32.47%)
Co-morbidities 0.51
Hypertension 162 (26.00%) 49 (21.21%)
Diabetes mellitus 124 (19.90%) 46 (19.91%)
Atrial fibrillation 78 (12.52%) 21 (9.09%)
Type of device 0.266
DR 426 (68.38%) 168 (72.73%)
VR 129 (20.71%) 46 (19.91%)
CRT-D 68 (10.91%) 17 (7.36)
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more prevalent, 757 (88.6%) versus 97 (11.4%) females. The
mean age of patients was 62.9  11.6 years old (range
18e88).
From the total 854 patients, 623 (73%) were subjected to
ICD implantation for primary and 231 (27%) for secondary
prevention.
Out of the same total, the majority of these patients 490
(57.4%) suffered from ischemic cardiomyopathy, 265 pa-
tients (31%) from non-ischemic dilated cardiomyopathy
(DCM), 41 (4.8%) from hypertrophic cardiomyopathy (HCM)
and 58 (6.8%) patients had a primary electrical disorder
(channelopathy). The baseline clinical characteristics of
our patients are illustrated in Table 1.
The distribution of ICDs was as follows: 69.6% of our
patients received a dual-chamber ICD, 20.5% received a
single-chamber ICD, and in 9.9% a CRT-D device was
implanted.
3.2. Mortality
During a mean follow-up of 11.2  7.8 years, 218 (25.5%)
patients died. Compared with the primary prevention
group, the incidence of all-cause mortality was significantly
higher in the secondary prevention patient group. In
particular, the cumulative incidence of mortality during
follow-up was 41.1% for secondary prevention patients and
19.7% for primary prevention patients, (log rankZ7.117
pZ0.008), (Fig. 2).
The deaths occurred mainly due to cardiovascular causes
(54.1%), followed by malignancies (25.7%) and other non-
cardiovascular causes (20.2%).
3.3. Defibrillator therapies
A total of 1,453 appropriate ICD interventions (ATP or
shock) were received by 248 patients (29%). The cumulative
incidence of appropriate therapy during follow-up was
23.4% in primary prevention patients, compared to 44.2% in
secondary prevention patients (log rank 8.362 p<0.004),
(Fig. 3).
From the 146 primary prevention patients who received
an appropriate therapy, the cumulative incidence of first
appropriate ICD therapy was 23.9% in the first year post-
implantation, which increased to 44.4% in the second year,
and in the fifth year reached 85.6%.0
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Figure 1 Number of implantation devices per year
1993e2013.From the 102 secondary prevention patients who
received an appropriate therapy, the cumulative incidence
of first appropriate ICD therapy was 21.6% in the first year
post-implantation, which increased to 34.3% in the second
year, and in the fifth year was 62.7%.
Notably 42 patients (4.9%) received their first appro-
priate therapy after device replacement.
The total number of appropriate defibrillator shocks was
1,108. One or more appropriate shocks were received by
184 patients; 131 in the primary prevention group and 53 in
the secondary prevention group.
In total, 331 inappropriate therapies occurred in 99 pa-
tients. The cumulative incidence of inappropriate therapies
during the mean follow-up period of 11.2  7.8 years was
11.6%. The majority (81.5%) were due to supraventricular
tachycardias, mainly atrial fibrillation.
3.4. Device replacements
During follow-up, 187 devices (21.9%) were replaced. ICD
recipients required their first device replacement after a
mean follow-up of 5.81.6 years; whereas, in CRT-D re-
cipients device replacement was required after a mean
follow-up of 4.51 years.
3.5. Device-related complications
There were 13 patients (1.5%) who suffered from a device-
related infection requiring device extraction or revision.
Lead-related complications were noted in 49 patients
Figure 2 All-cause mortality. Kaplan Meier curves of all-cause mortality for primary and secondary prevention ICD recipients.
Figure 3 Appropriate therapy. Kaplan-Meier curves of appropriate therapy for primary and secondary prevention ICD recipients.
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repositioning, and in 17 patients the lead was inactivated.
In 22 (2.6%) of these cases, failure was attributed to leads
with known lead failure (Sprint Fidelis or Riata leads).
3.6. Other analyses
We also performed multivariate Cox regression analysis on
the risk of mortality or appropriate therapies with the un-
derlying heart disease type and co-morbidities (hyperten-
sion, diabetes, atrial fibrillation). No association between
change in risk and any of the covariates was identified.
4. Discussion
The main findings of the current registry from the only ICD
implantation center on Crete, the University Hospital of
Heraklion, are summarized as follows: during a long period
of 21 years, 854 ICDs were implanted; 25.5% of ICD re-
cipients died and 29% received an appropriate therapy by
their device. Most patients received an ICD for primary
prevention of SCD, and the majority suffered from ischemic
cardiomyopathy. Inappropriate shocks occurred in 11.6%,
device-related infection was noted in 1.5% and lead failure
in 2.6% of our patients. During the study period, 21.9% of
the patients had their device replaced, and it is noteworthy
that 4.9% of these received their first appropriate therapy
after device replacement.
To the best of our knowledge, this report describes the
largest ICD registry from Greece to be published to date.
Heraklion’s implantation center is one of 24 implantation
centers in Greece, and it is worth highlighting that such
registries are extremely useful, as they provide all physi-
cians, research scientists, healthcare providers, healthcare
economists and politicians the opportunity to evaluate a
wide range of data and to extract valuable information
from the elaborated findings, as they provide real-world
data, which may be used to improve Greek health, and
moreover, the Greek healthcare system.
The majority of ICD implantations (73%) at our center
were for primary prevention of SCD. This finding is in
contrast to previously published registry data from North
Greece, where the majority of patients received an ICD for
secondary prevention (72%). This difference can be
explained from the registration time period. The North
Greece center recorded ICD implantations from 2002e2007,
before the publication of large randomized clinical trials
that influenced international guidelines and clinical prac-
tice on the primary prevention of SCD.9
A typical example of this shift in trend was demon-
strated by the Italian registry, where it was reported that in
2005, 44.2% of the ICD procedures were for primary pre-
vention and 55.8% for secondary prevention; but in 2007,
55.7% of such implantations were for primary prevention
and 44.3% for secondary prevention.10
Our percentages are similar to other European registries,
demonstrating that current international guidelines have
been adopted by Greek cardiologists.11,12
Undoubtedly, ICDs improve survival in patients at high
risk of SCD. This benefit is confirmed after a relatively short
period of follow-up time. In MADIT-II and SCD-HeFT survivalwas 19.5 and 46.1 months, respectively.4,7 Data on the
long-term efficacy of defibrillator therapies are rare. In a
primary prevention population, an extended 8-year follow-
up of MADIT-II demonstrated a sustained survival benefit.13
In secondary prevention patients, the benefit of ICD over
amiodarone was confirmed after an extended follow-up of
11 years, in a subset of CIDs.14
Whether these benefits differ from those of trial-eligible
patients receiving an ICD in routine clinical practice re-
mains a challenging question.
Comparing mortality during long-term follow-up in ran-
domized clinical trials and other registries with similar
follow-up, the mortality of primary prevention patients in
our registry was very low (25.5%). In MADIT-II, 44% of the
ICD recipients died after 8 years. A very recently published
registry from Leiden University showed a high rate of
mortality (42%) in the same population during a 12-year
follow-up.15
This difference could be attributed to the fact that our
patients seem to have a lower rate of co-morbidities, such
as diabetes, hypertension or atrial fibrillation, clinical risk
factors that are associated with worse prognosis in ICD
recipients.16
Appropriate therapies were delivered in both primary
and secondary prevention patients, but as expected, the
prevalence of these therapies was higher in patients who
already have survived an episode of malignant arrhythmias.
The cumulative incidence of appropriate therapies in the
current registry is lower than that observed in the Dutch
registry,11,15 but is higher than in Danish patients.12
It is notable that the first appropriate therapy took
longer to occur in primary prevention patients than in
secondary prevention patients. In some cases, the first
appropriate therapy occurred when the life duration of the
first device had expired, and thus, why replacement of ICDs
appears to be indicated for all patients.
It is noteworthy that the percentage of women in our
registry is very low, but in almost all registries, the per-
centage of men approaches 80%.11e13
Finally, no fatal complications were recorded during
implantation. The percentage of infections was expected,
in accordance with the international bibliography, while
the lead problems were already known.
The results from our study are very encouraging, espe-
cially regarding infections, which are the most important
complication and nightmare for clinicians and patients
alike. These low rates were achieved mainly due to the high
level of experience of the medical team and operating
room staff, coupled with adherence to current periproce-
dural recommendations.17
This is a single-center ICD registry in an isolated pre-
fecture of South Greece, which corresponds to 1/20 of the
total population of the country, which could be a limita-
tion, but conversely, it is a fact that studies in isolated
areas, such as the island of Crete, have the advantage of a
well-controlled population without missing data. Moreover,
the implanters were the same doctors responsible for the
follow-up and programming of the devices. Data were
collected prospectively and accurately, in order to record
the long-term clinical outcomes of consecutive patients
who were subjected to ICD implantation. However, the
prolonged period of the study has several limitations. For
252 E.M. Kanoupakis et al.example, the population is less homogeneous because the
guidelines for ICD recipients have evolved and therapeutic
interventions are differentiated, due to device-technology
progress. The annual implantation rate illustrates the in-
cremental number of patients, considering that the in-
dications for ICDs have broadened, due to publication of
large randomized, primary prevention trials.
5. Conclusions
This single-center registry includes all ICD recipients on the
island of Crete and demonstrates the long-term efficacy of
these devices in preventing SCD and total mortality. How-
ever, the substantial proportion of patients without any
therapy remains high. Additional and joint efforts are
required to improve the predictive value of risk stratifica-
tion techniques.
Moreover, the low rate of complications confirms the
safety of this type of therapy. However, additional collab-
oration between physicians and medical device makers is
needed, in order to address the weak links of inappropriate
shocks and lead failures.
Currently, in the era of economic recession, concerns
about the economics of health arise from all stakeholders.
Therefore, medical and economic reasons logically call for
a nationwide Greek registry that will evaluate all of the
factors that influence the implantation of these life-saving
devices in the battle against sudden cardiac death.References
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